@techinvestoor · Long PRME

$PRME Only 150X higher than PRME market cap. No biggie smalls

Around $100 billion. Vertex's CF franchise alone drives most of its $127B market cap on ~$12B yearly chronic revenue at $300k+ per patient. A true one-time functional cure for the ~40k US / 100k+ global patients, priced like other gene therapies at $2-4M, captures that lifetime

Read asLong PRME

Since the call—

unrankedThe analyst's rank today

High · 0.91Confidence

Mon, Oct 19Tweeted

Tue, Oct 20 closeCounted from

1% of the basket · day 0fades out by Nov 30

Rank per close

Counts from the Tue, Oct 20 close, which is not scored yet.